Why the study?
Does a polymer-free sirolimus-eluting stent improve long-term clinical outcomes compared to a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus?
Does a polymer-free sirolimus-eluting stent improve long-term clinical outcomes compared to a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus?
At 5 years of follow-up, a polymer-free sirolimus-eluting stent showed similar clinical outcomes to a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus.
Answers are grounded in this paper and cite their sources.
Either stent is acceptable in diabetes without outcome differences; extends RCT evidence of long-term equivalence.
OBJECTIVES: The long-term performance of polymer-free stent systems in patients with diabetes mellitus has not been investigated extensively. This study reports long-term results of the LIPSIA Yukon trial which compared the polymer-free sirolimus-eluting Yukon Choice stent with the polymer-based paclitaxel-eluting Taxus Liberté stent in this subpopulation. At 9 months, the Yukon Choice stent failed to show non-inferiority in terms of the primary end point late lumen loss, while no significant difference in clinical outcome was detected. METHODS AND RESULTS: The LIPSIA Yukon trial randomized 240 patients with diabetes mellitus to a polymer-free sirolimus eluting stent (Yukon Choice, Translumina) versus a polymer-based paclitaxel-eluting stent (Taxus Liberté, Boston Scientific). Clinical follow-up was conducted with a standardized telephone follow-up and all events were centrally adjudicated. Follow-up was available for 98.3% of patients after a median of 5.0 years. The incidence of all-cause death (16.9% versus 14.0%, P = 0.67), respectively definite or presumed cardiovascular death (7.6% versus 8.8%, P = 0.94) were similar in the Yukon Choice and the Taxus Liberté group. There were no significant differences in the rates of myocardial infarction (9.3% versus 7.9%, P = 0.88), definite stent thrombosis (0.8% versus 0.9%, P = 1.0), target lesion revascularization (15.3% versus 15.8%, P = 1.0), target vessel revascularization (18.6% versus 23.7%, P = 0.44), non-target vessel revascularization (18.6% versus 26.3%, P = 0.21), and stroke (3.4% versus 4.4%, P = 0.96) between patients assigned to the Yukon Choice and the Taxus Liberté stent. CONCLUSION: At 5 years of follow-up, clinical outcome was similar between the polymer-free sirolimus-eluting Yukon Choice stent and the polymer-based paclitaxel-eluting Taxus Liberté stent.
No takes yet. Share an insight, caveat, or question.
Stiermaier et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: